Ginkgolide B Reduces the Degradation of Membrane Phospholipids to Prevent Ischemia/Reperfusion Myocardial Injury in Rats

Hong Xia Pei, Rong Hua, Cha Xiang Guan, Xiang Fang

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Platelet-activating factor (PAF), a bioactive phospholipid, plays an important role in the integrity of the cellular membrane structure, and is involved in the pathogenesis of myocardial ischemia/reperfusion (IR) injuries. In this study, we tested the hypothesis that blockage of PAF receptor by BN 52021 (Ginkgolide B) can prevent IR-induced degradation of the myocardial membrane phospholipid, and deterioration of the cardiac function. Rat hearts in situ were subjected to 5 min ischemia and followed by 10 min reperfusion. Cardiac performances during periods of ischemia and reperfusion were monitored, and the amount of membrane phospholipids was analyzed. Myocardial total phospholipids, phosphatidylcholine, and phosphatidylethanolamine were decreased significantly in ischemia-reperfusion rat hearts compared with those of sham-operated rat hearts. Degradation of the membrane phospholipid was accompanied by the deterioration of cardiac functions and increase in serum lactate dehydrogenase (LDH) activity. BN 52021 (15 mg/kg), given by intravenous infusion 10 min prior to the left anterior descending coronary artery occlusion, reduced IR-related degradation of the myocardial phospholipids, the activity of serum LDH, and was concomitant with improvement of cardiac function. Furthermore, we demonstrated that the production of PAF was increased and BN 52021 decreased cellular damage in cultured anoxic cardiomyocytes. These results indicated that PAF antagonist BN 52021 has a protective effect against IR-induced myocardial dysfunction and degradation of the membrane phospholipids.

Original languageEnglish (US)
Pages (from-to)233-239
Number of pages7
JournalPharmacology
Volume96
Issue number5-6
DOIs
StatePublished - Nov 1 2015

Fingerprint

ginkgolide B
Reperfusion Injury
Phospholipids
Ischemia
Reperfusion
Membranes
Platelet Activating Factor
L-Lactate Dehydrogenase
Myocardial Reperfusion Injury
Myocardial Reperfusion
Coronary Occlusion
Cellular Structures
Serum
Phosphatidylcholines
Cardiac Myocytes
Intravenous Infusions
Myocardial Ischemia

Keywords

  • Ginkgolide B (BN 52021)
  • Ischemia-reperfusion
  • Membrane phospholipid
  • Myocardial injury
  • Platelet-activating factor

ASJC Scopus subject areas

  • Pharmacology

Cite this

Ginkgolide B Reduces the Degradation of Membrane Phospholipids to Prevent Ischemia/Reperfusion Myocardial Injury in Rats. / Pei, Hong Xia; Hua, Rong; Guan, Cha Xiang; Fang, Xiang.

In: Pharmacology, Vol. 96, No. 5-6, 01.11.2015, p. 233-239.

Research output: Contribution to journalArticle

@article{3dd60e2546544b9aa9385e1872132b45,
title = "Ginkgolide B Reduces the Degradation of Membrane Phospholipids to Prevent Ischemia/Reperfusion Myocardial Injury in Rats",
abstract = "Platelet-activating factor (PAF), a bioactive phospholipid, plays an important role in the integrity of the cellular membrane structure, and is involved in the pathogenesis of myocardial ischemia/reperfusion (IR) injuries. In this study, we tested the hypothesis that blockage of PAF receptor by BN 52021 (Ginkgolide B) can prevent IR-induced degradation of the myocardial membrane phospholipid, and deterioration of the cardiac function. Rat hearts in situ were subjected to 5 min ischemia and followed by 10 min reperfusion. Cardiac performances during periods of ischemia and reperfusion were monitored, and the amount of membrane phospholipids was analyzed. Myocardial total phospholipids, phosphatidylcholine, and phosphatidylethanolamine were decreased significantly in ischemia-reperfusion rat hearts compared with those of sham-operated rat hearts. Degradation of the membrane phospholipid was accompanied by the deterioration of cardiac functions and increase in serum lactate dehydrogenase (LDH) activity. BN 52021 (15 mg/kg), given by intravenous infusion 10 min prior to the left anterior descending coronary artery occlusion, reduced IR-related degradation of the myocardial phospholipids, the activity of serum LDH, and was concomitant with improvement of cardiac function. Furthermore, we demonstrated that the production of PAF was increased and BN 52021 decreased cellular damage in cultured anoxic cardiomyocytes. These results indicated that PAF antagonist BN 52021 has a protective effect against IR-induced myocardial dysfunction and degradation of the membrane phospholipids.",
keywords = "Ginkgolide B (BN 52021), Ischemia-reperfusion, Membrane phospholipid, Myocardial injury, Platelet-activating factor",
author = "Pei, {Hong Xia} and Rong Hua and Guan, {Cha Xiang} and Xiang Fang",
year = "2015",
month = "11",
day = "1",
doi = "10.1159/000438945",
language = "English (US)",
volume = "96",
pages = "233--239",
journal = "Pharmacology",
issn = "0031-7012",
publisher = "S. Karger AG",
number = "5-6",

}

TY - JOUR

T1 - Ginkgolide B Reduces the Degradation of Membrane Phospholipids to Prevent Ischemia/Reperfusion Myocardial Injury in Rats

AU - Pei, Hong Xia

AU - Hua, Rong

AU - Guan, Cha Xiang

AU - Fang, Xiang

PY - 2015/11/1

Y1 - 2015/11/1

N2 - Platelet-activating factor (PAF), a bioactive phospholipid, plays an important role in the integrity of the cellular membrane structure, and is involved in the pathogenesis of myocardial ischemia/reperfusion (IR) injuries. In this study, we tested the hypothesis that blockage of PAF receptor by BN 52021 (Ginkgolide B) can prevent IR-induced degradation of the myocardial membrane phospholipid, and deterioration of the cardiac function. Rat hearts in situ were subjected to 5 min ischemia and followed by 10 min reperfusion. Cardiac performances during periods of ischemia and reperfusion were monitored, and the amount of membrane phospholipids was analyzed. Myocardial total phospholipids, phosphatidylcholine, and phosphatidylethanolamine were decreased significantly in ischemia-reperfusion rat hearts compared with those of sham-operated rat hearts. Degradation of the membrane phospholipid was accompanied by the deterioration of cardiac functions and increase in serum lactate dehydrogenase (LDH) activity. BN 52021 (15 mg/kg), given by intravenous infusion 10 min prior to the left anterior descending coronary artery occlusion, reduced IR-related degradation of the myocardial phospholipids, the activity of serum LDH, and was concomitant with improvement of cardiac function. Furthermore, we demonstrated that the production of PAF was increased and BN 52021 decreased cellular damage in cultured anoxic cardiomyocytes. These results indicated that PAF antagonist BN 52021 has a protective effect against IR-induced myocardial dysfunction and degradation of the membrane phospholipids.

AB - Platelet-activating factor (PAF), a bioactive phospholipid, plays an important role in the integrity of the cellular membrane structure, and is involved in the pathogenesis of myocardial ischemia/reperfusion (IR) injuries. In this study, we tested the hypothesis that blockage of PAF receptor by BN 52021 (Ginkgolide B) can prevent IR-induced degradation of the myocardial membrane phospholipid, and deterioration of the cardiac function. Rat hearts in situ were subjected to 5 min ischemia and followed by 10 min reperfusion. Cardiac performances during periods of ischemia and reperfusion were monitored, and the amount of membrane phospholipids was analyzed. Myocardial total phospholipids, phosphatidylcholine, and phosphatidylethanolamine were decreased significantly in ischemia-reperfusion rat hearts compared with those of sham-operated rat hearts. Degradation of the membrane phospholipid was accompanied by the deterioration of cardiac functions and increase in serum lactate dehydrogenase (LDH) activity. BN 52021 (15 mg/kg), given by intravenous infusion 10 min prior to the left anterior descending coronary artery occlusion, reduced IR-related degradation of the myocardial phospholipids, the activity of serum LDH, and was concomitant with improvement of cardiac function. Furthermore, we demonstrated that the production of PAF was increased and BN 52021 decreased cellular damage in cultured anoxic cardiomyocytes. These results indicated that PAF antagonist BN 52021 has a protective effect against IR-induced myocardial dysfunction and degradation of the membrane phospholipids.

KW - Ginkgolide B (BN 52021)

KW - Ischemia-reperfusion

KW - Membrane phospholipid

KW - Myocardial injury

KW - Platelet-activating factor

UR - http://www.scopus.com/inward/record.url?scp=84942247801&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942247801&partnerID=8YFLogxK

U2 - 10.1159/000438945

DO - 10.1159/000438945

M3 - Article

C2 - 26382046

AN - SCOPUS:84942247801

VL - 96

SP - 233

EP - 239

JO - Pharmacology

JF - Pharmacology

SN - 0031-7012

IS - 5-6

ER -